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Abstract
MicroRNAs (miRNAs) are small non-coding RNAs with regulatory roles, which are involved in a broad spectrum of
physiological and pathological processes, including cancer. A common strategy for identification of miRNAs involved in cell
transformation is to compare malignant cells to normal cells. Here we focus on identification of miRNAs that regulate the
aggressive phenotype of melanoma cells. To avoid differences due to genetic background, a comparative high-throughput
miRNA profiling was performed on two isogenic human melanoma cell lines that display major differences in their net
proliferation, invasion and tube formation activities. This screening revealed two major cohorts of differentially expressed
miRNAs. We speculated that miRNAs up-regulated in the more-aggressive cell line contribute oncogenic features, while the
down-regulated miRNAs are tumor suppressive. This assumption was further tested experimentally on five candidate tumor
suppressive miRNAs (miR-31, -34a, -184, -185 and -204) and on one candidate oncogenic miRNA (miR-17-5p), all of which
have never been reported before in cutaneous melanoma. Remarkably, all candidate Suppressive-miRNAs inhibited net
proliferation, invasion or tube formation, while miR-17-5p enhanced cell proliferation. miR-34a and miR-185 were further
shown to inhibit the growth of melanoma xenografts when implanted in SCID-NOD mice. Finally, all six candidate miRNAs
were detected in 15 different metastatic melanoma specimens, attesting for the physiological relevance of our findings.
Collectively, these findings may prove instrumental for understanding mechanisms of disease and for development of novel
therapeutic and staging technologies for melanoma.
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Introduction
Melanoma, an aggressive malignancy arising from melanocytes,
is one of the main life-threatening malignancies of our era. While it
accounts for nearly 4% of all skin cancers, it causes 75% of skin
cancer–related deaths worldwide and is considered to be the most
common fatal malignancy of young adults [1]. Transformation
and development of metastasis require stepwise acquisition of
aggressive characteristics. These include, for example, uncon-
trolled growth, resistance to apoptosis, motility, proteolytic
capacity and adhesion (reviewed in [2,3]). In addition, plasticity
of melanoma cells is evident by their ability to form tube-like
structures [4]. These functional vascular-like structures are
comprised of tumor cells [5] and their presence is associated with
poor prognosis [6,7]. Recent development of targeted therapy for
melanoma emphasizes the importance of molecular delineation of
the underlying mechanisms of pathogenesis [8].
MicroRNAs (miRNAs) are small, non-coding, 19–22 nucleotide
long RNA molecules, which function as specific epigenetic
regulators of gene expression by inhibiting protein translation,
leading mRNA to degradation, or both [9,10]. Once processed
from their distinctive hairpin transcripts and loaded into the
Argonaute protein of the silencing complex, the miRNAs pair with
cytoplasmic mRNA to direct posttranscriptional repression. The
‘‘seed’’ region, which is found between nucleotides 2 to 8 of the
mature miRNA, binds to complementary regions in the 39 un-
translated region (39-UTR) of target mRNA. To date, close to
1000 human miRNAs have been identified [11], which are
thought to regulate at more than 50% of human genes [12].
miRNAs are involved in the regulation of many biological
processes, such as embryonic development, cell differentiation, cell
cycle, apoptosis and angiogenesis (reviewed in [13]). They are also
directly implicated in cancer development, progression and
metastasis in-vitro, in-vivo and reported even in patients [10,14].
In some cases, cancer is facilitated by the loss of certain miRNAs,
such as miR-15/16 cluster in chronic lymphocytic leukemia [15],
miR-34a in uveal melanoma [16] and miR-31 in mesothelioma
[17]. The loss of these miRNAs enhances invasiveness, migration
and proliferation of cancer cells. In other cases, cancer is facilitated
by the over-expression of other miRNAs, such as miR-17-92
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18936cluster [13,18], which promotes migration and invasion in several
malignancies.
Currently, our knowledge on the roles of miRNAs in melanoma
development and progression is still limited. Recently, several
comparative miRNA profiling studies of normal melanocytes and
melanoma cells revealed: 1) Groups of miRNAs associated with
malignant transformation, progression and metastatic potential
[19]; 2) Specific expression profiles that were associated with
mutational status and survival [20]; 3) Differential miRNA patterns
in melanoma of young adults and older adults [21]; and 4)
Predictionofpost-recurrencesurvival [22].Yet noneof thesestudies
described miRNAs that directly determine aggressive features of
cutaneous melanoma, such as enhanced proliferation, motility and
invasion. Few inhibitory miRNAs were identified in melanoma,
including miR-34a (uveal melanoma) [16], miR-193b [23], let-7a
[24], and miR-211 [25,26], while miR-182 [27] and miR-221/222
[28]were shown to stimulate metastatic potential of melanoma cells.
Given the critical evaluation of aggressive versus not aggressive
melanoma, and the potential of therapeutics, we find it imperative
to learn the molecular events of aggressive melanoma.
Here we focus on high-throughput identification of miRNAs that
are directly involved in determination of an aggressive melanoma
cell phenotype. Two isogenic melanoma cell-lines with a different
aggressive pattern, the highly aggressive C8161 cells and the poorly
aggressive C81-61 cells, were subjected to differential high-
throughput screening of miRNAs. We hypothesized that due to
the isogenic background of the cells, the differentially expressed
miRNA groups would be enriched for miRNAs with a direct effect
on aggressive melanoma features. Indeed, we provide experimental
evidence in-vitro, in-vivo and in clinical melanoma specimens that
previously known tumor-suppressive and tumor-promoting
miRNAs fit this hypothesis. Remarkably, we describe new miRNAs
with little information regarding their role in cancer, such as miR-
185. The scientific and translational implications of this study are
discussed.
Results
Differential aggressiveness of melanoma isogenic cell
lines
The highly aggressive (HAG) C8161 and poorly aggressive
(PAG) C81-61 cutaneous melanoma cell lines were derived from
different metastases from the same patient [29]. The differential
aggressive phenotype of the HAG and PAG cells was confirmed by
four different functional assays: proliferation, invasion through
matrigel, tube formation in matrigel and formation of tumors in
xenografted mice. Indeed, HAG cells displayed substantially
higher proliferation, invasion and tube formation capabilities in-
vitro, than PAG cells (Figure 1, A–C). Moreover, subcutaneous
injection of 1610
6 HAG cells formed tumors in SCID-NOD mice
within five days post injection, with an average xenograft size of
780 mm
3 by day 30. In contrast, injection of 1610
6 PAG cells did
not develop into measurable tumors within 30 days (Figure 1D).
Small PAG tumors (,200 mm
3) were observed .90 days post
injection of PAG cells (data not shown).
Differential expression profile of miRNAs among HAG
and PAG cells
The remarkable phenotypic difference between the two isogenic
melanoma lines comprised the platform for studying epigenetic
regulation of aggressive features by miRNAs. A comparative high-
throughput profiling of miRNAs was performed. Importantly, a set
of 81 miRNAs were expressed at higher levels in the HAG as
Figure 1. Differential aggressiveness between two isogenic melanoma lines. (A) Proliferation was determined with standardized XTT
colorimetric assay 24 h after seeding. The number of HAG cells was determined as 100%. Figure shows a representative experiment out of three
performed; (B) The percentage of invading cells tested in a 20 h matrigel invasion assay. Results were corrected for proliferation rate. Figure shows a
representative experiment out of three performed; (C) HAG cells or PAG cells were tested for tube formation activity. Representative whole field
microphotographs are shown from a representative experiment, out of three performed; (D) The average tumor masses formed in SCID-NOD mice 30
days post injection of 1610
6 cells of HAG or PAG cell lines. Each group included at least six mice.
doi:10.1371/journal.pone.0018936.g001
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high). Another set of 69 miRNAs
was expressed at lower levels in the HAG as compared to the PAG
cells (HAG
low). A group of 48 miRNAs out of the 81 HAG
high
miRNAs were not expressed at all in the PAG cells (Figure 2A),
while 56 miRNAs out of the 69 HAG
low miRNAs were not
detected in HAG cells (Figure 2B). The rest of the differentially
expressed miRNAs were found in both cell lines at different,
quantifiable, amounts (Figure 2C). We hypothesized that these
miRNA clusters would be enriched for miRNAs that are involved
in direct regulation of the distinct phenotypic differences. More
specifically, we speculated that the HAG
low miRNAs would be
enriched in miRNAs accounting for suppressive effects on various
cell features e.g. proliferation (Suppressive miRNAs), while the
HAG
high miRNAs would be enriched in miRNAs with oncogenic
or tumor-promoting effects (Oncogenic miRNAs) (Figure 2).
Selection of miRNAs for specific functional assays
We focused mainly on HAG
low miRNAs, which are presumably
tumor-suppressive and could provide the basis for novel lines of
therapy for melanoma. miRNAs with tumor-suppressive potential
were analyzed for predicted targets with TargetScan algorithm
[30] and for the affected biological processes with miRanda
(miRpath) algorithm [31]. All the potentially affected biological
processes were ranked according to the overall P value, with a cut-
off of ,0.01. Further focus on the robust processes was enabled by
selecting biological processes that included at least 30 candidate
target genes. Remarkably, these computational steps highlighted
four biological processes that are highly involved in cancer,
including Wnt pathway (82 genes, P=1.7610
29), focal adhesion
(100 genes, P=8.6610
29), MAPK pathway (120 genes,
P=2 610
27) and Phosphatidylinositol pathway (35 genes,
P=7.2610
23). Twenty nine of the miRNAs were predicted to
target all four processes, with only 12 having been reported to
experimentally exert a suppressive effect in any cancer.
Altogether, five candidate Suppressive miRNAs, which have
never been studied in melanoma, were selected for cloning and
experimental tests. Three miRNAs were within expression range
(miR-34a, miR-185 and miR-204, Figure 2C) and two which were
silenced (miR-31 and miR-184, Figure 2B) in the HAG cells. miR-
17 was selected as an example for candidate Oncogenic miRNA
(Figure 2C). The differential expression of each of these miRNAs
was validated in two independent RNA preparations (data not
shown). Different roles of miR-17, miR-31 and miR-34a in cancer
have been reported before, although never in cutaneous
melanoma. In contrast, there is scarce evidence on the roles of
miRNAs -184, -185 and -204 in cancer. Exemplar predicted roles
in biological and molecular functions concerning these miRNAs
are summarized in Supplementary Table S1 [32].
Expression profile of selected miRNAs in clinical
melanoma specimens
Fifteen patient-derived primary cultures of melanoma were
analyzed for the expression level of the selected miRNAs. All
melanoma cultures were established from distant metastases.
Additional data on the patients is provided in Supplementary
Table S2. As expected, a considerable variability in miRNA
expression was observed among the individual specimens, mainly
of miR-31 (Figure 3). The mean expression level of most candidate
Suppressive miRNAs in the clinical specimens was between the
corresponding miRNA values in the PAG and HAG cells, except
for miR-185 and miR-31. While the mean level of miR-185 was
very close to the PAG cells, miR-31 levels were clearly higher even
than PAG cells (Figure 3). In contrast, the mean expression of the
candidate Oncogenic miR-17 among the clinical specimens was
Figure 2. Differential miRNA expression profile in HAG and PAG cells. (A) The list of miRNAs that are expressed in the HAG cells, but not in
the PAG cells; (B) The list of miRNAs that are expressed in the PAG cells, but not in the HAG cells; (C) Relative expression of miRNAs that are expressed
in both HAG and PAG cells. Expression of HAG-to-PAG ratio (Y-axis) is shown as 2‘-DDCt. HAG
low represents miRNAs with low HAG-to-PAG ratio.
HAG
high represents miRNAs with high HAG-to-PAG ratio.
doi:10.1371/journal.pone.0018936.g002
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patterns in clinical specimens directly shows that most candidate
Suppressive miRNAs, except for miR-31, are expressed at
significantly lower levels than the candidate Oncogenic miR-17
(Figure 3). These results concur with our hypothesis and suggest
that the approach used to identify functional Suppressive and
Oncogenic miRNAs has physiologically-relevant grounds.
Regulation of aggressive phenotype of melanoma cells
by candidate Suppressive miRNAs
Determination of miRNAs that inhibit the aggressive phenotype
of melanoma could become a basis for development of new
platforms for cancer therapy. In order to evaluate the functional
effect of the candidate Suppressive miRNAs on the aggressive
features of melanoma, we cloned and stably over-expressed them
in HAG cells to evaluate their effect in-vitro and in-vivo. An empty
vector served as control. An over-expression of at least 50-fold was
confirmed by real time PCR (Figure 4A). The phenotype of the
transduced cells was tested in-vitro for proliferation, invasion and
tube formation activities. Remarkably, a substantial and consistent
inhibition in net proliferation was conferred by miR-31, miR-34a,
miR-184 and miR-185 as compared to the control cell (Figure 4B).
miR-204 did not inhibit the proliferation of HAG cells (Figure 4B).
In contrast, miR-204 markedly inhibited the invasion activity of
HAG cells (Figure 4C). Invasion was similarly inhibited by miR-
184, but not by the other Suppressive miRNAs (Figure 4C).
Tube formation activity was substantially inhibited by miR-34a
and miR-185, and more mildly by miR-31 and miR-184, but not
by miR-204, as compared to control (Figure 5, A–F). Quantifi-
cation of total tube length was performed using ImageJ.
Importantly, the qualitative assessment of micrographic captures
(Figure 5, A–F) concurred with the quantitative total length
analysis (Figure 5G). The differential effects of the miRNAs could
not be simply attributed to their differential over-expression
intensities (Figure 4A). Almost all cells were viable when assayed,
as evident by ,5% positive trypan blue staining (data not shown).
Taken together, all five candidate Suppressive miRNAs indeed
exerted significant inhibitory effects on various aggressive features
of melanoma cells. This concurs with their substantial downreg-
ulation in the HAG cells (Figure 2) and their overall low expression
in clinical specimens (Figure 3). This also strengthens our high-
throughput miRNA screening and emphasizes its reliability.
Facilitation of aggressive phenotype of melanoma cells
by candidate Oncogenic miRNA
Since the miRNA 17–92 clusters’ functional role in cancer is well
established, yet never has it been tested in cutaneous melanoma, we
evaluated miR-17 for its effect on the aggressiveness of PAG cells.
miR-17 was cloned and stably over-expressed in the PAG cells. An
emptyvector servedascontrol. A 25-fold over-expressionofmiR-17
was verified by real time PCR (Figure 6A). Importantly, miR-17-
transduced PAG cells displayed a significantly enhanced prolifer-
ative activity (Figure 6B) but not invasive ability (Figure 6C) or tube
formation activity (data not shown). These results support the
potentially oncogenic effects of miR-17 in melanoma.
miRNA-mediated regulation of aggressive melanoma
features in-vivo
In cancer biology, in-vitro results often do not necessarily reflect
in-vivo behavior. To this end, the effects of selected Suppressive
Figure 3. Expression analysis of selected miRNAs in clinical melanoma specimens. The expression of candidate Suppressive or Oncogenic
miRNAs, as indicated, in HAG (striped bars), PAG (gray bars) and 15 low-passage primary cultures of metastatic melanoma (black bars). Horizontal line
depicts the mean expression. Y-axis denotes absolute expression of each miRNA after normalization to the U6 endogenous control in each specimen,
and is presented as 1/DCt.
doi:10.1371/journal.pone.0018936.g003
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models. The effect of the Suppressive miRNAs, miR-34a and
miR-185 on tumor growth was measured following subcutaneous
injection of 3610
5 HAG transductants. Tumor masses were
monitored for 28 days post injection. Over-expression of specific
miRNAs was confirmed pre-injection (data not shown). Impor-
tantly, a statistically significant inhibition in tumor growth was
observed in both miR-34a and miR-185 transducatnts, as
compared to control tumors (Figure 7A). Concurring with these
results, ex-vivo weighing of tumor explants upon termination of
the experiments confirmed that the average tumor mass of both
miR-34a and miR-185 transducatnts was lower than Mock-
transduced tumors (Figure 7B). The in-vivo over-expression of the
transduced miRNAs was confirmed in the tumor explants
(Figure 7C). These results corroborate with the expression
results and functional suppressive effects demonstrated in-vitro
(Figure 4–5).
Discussion
Up to date, most attempts to characterize the roles of miRNAs
in cancer in general or melanoma in particular, have focused on
differential profiling of normal cells compared to their malignant
counterpart cells [19,20]. This approach enabled the identification
of miRNAs that participate in the process of malignant
transformation. Here we focused on identification of miRNAs
that directly regulate cancer aggressive features of melanoma cells.
The objective of this approach was to map the miRNAs that could
be involved mechanistically in different disease phenotypes and
eventually delineate their regulatory role of aggressive cancer
features. We used two isogenic matched melanoma cell lines that
were derived of two different metastases from the same patient.
These cell lines significantly differ in their invasive, proliferative
and tumorigenic properties (Figure 1). Due to the shared genetic
background of the cells, our rationale was that the differential
expression of miRNAs would correlate well with their differential
aggressive phenotype.
High-throughput screening revealed a large cohort of differen-
tially expressed miRNAs between highly (HAG) and poorly (PAG)-
aggressive melanoma cell-lines (Figure 2). We hypothesized that
HAG
low miRNAs are suppressive and that HAG
high miRNAs are
oncogenic. Indeed, we provide substantial evidence supporting our
hypothesis, by ectopic expression of five selected HAG
low miRNAs
in HAG cells (Figures 4, 5, 7) and one HAG
high miRNA in PAG
cells, as a representative of this group (Figure 6). This is the first
report to successfully demonstrate a systematic approach for a
methodological identification of miRNAs that directly regulate
aggressive cancer features. The wealth of identified miRNAs that
regulate features of melanoma cell aggressiveness supports the use
of isogenic cell lines with differential phenotype as a screening
platform.
The expression of these miRNAs was validated in 15 low-
passage primary cultures, with the mean level of miR-17 being
higher than that of the Suppressive miRs, thus confirming the
physiological relevance (Figure 3). The expression of these
miRNAs should be further studied in the future in progression
tissue microarrays, and their prognostic value tested accordingly.
In the present work we focused on a group of either well
characterized miRNAs known to have a role in other malignancies
(miR-17, miR-31 and miR-34a), and on a second group of
relatively unstudied miRNAs with regard to their role in malignant
processes (miR-184, miR-185, miR-204). Noteworthy, the roles of
all of these miRNAs have never been described in cutaneous
melanoma.
miR-31 was reported to exert inhibitory effects on metastasis in
breast cancer [33,34] and in mesothelioma [17], while it has a
potential oncogenic role in as head and neck squamous cell
carcinoma and lung cancer [35,36]. miR-34a was consistently
reported as a suppressive miRNA in many malignancies [37]. Our
results concur with the suggested inhibitory role for miR-34a and
miR-31. Moreover, miR-34a has been previously reported to
target c-Met [16]. Since c-Met has been reported to participate in
tubulogenesis processes through the c-Met/HGF system [38], it is
tempting to speculate that the mechanism by which miR-34a
inhibits tube formation is via this gene. The oncogenic properties
of miR-17-5p were discussed in earlier publications in other
malignancies [13]. In agreement with these reports, ectopic
expression of miR-17-5p in the PAG cells enhanced proliferation
rate (Figure 6B).
Figure 4. Candidate Suppressive miRNAs inhibit proliferation
and invasion of melanoma cells. (A) Verification of over-expression
of miRNAs in HAG transductants, as compared to mock-transduced
cells. Y-axis denotes fold change above Mock-transduced cells. (B) Net
proliferation of the transductants was quantified with standardized XTT
test. The number of cells was determined 48 h after seeding. The
number of Mock-transductants was determined as 100%. Figure shows
a representative experiment out of three performed. (C) Invasion
activity of transductants was quantified with 20 h-matrigel invasion
assay, with correction for proliferation. The invasion rate of Mock-
transduced cells was determined as 100%. Figure shows a representa-
tive experiment out of 3 performed. * denotes P,0.05, ** denotes
P,0.01 (2-tailed t-test).
doi:10.1371/journal.pone.0018936.g004
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miR-204 in cancer. Most current studies on miR-184 and miR-
204 focus on their roles in development and morphogenesis, which
could be predicted computationally (Supplementary Table S1).
The few publications concerning miR-184 in cancer showed
contradictory effects, either suppressive [39] or oncogenic [40]. A
single report showed that miR-204 inhibited metastasis in head
and neck squamous cell carcinoma [41]. Another report described
downregulation of miR-204 in highly invasive melanoma sub-line
compared to its non-invasive isogenic counterpart [19], supporting
our findings regarding the invasion-inhibiting activity of miR-204
(Fig. 4C). miR-185 is still mostly unstudied, but recently it was
demonstrated to exert suppressive effects in several malignancies
through targeting Six1 oncogene [42,43]. The future challenge
would be to delineate the target gene networks of these miRNAs
and understand the molecular basis for their tumor-suppressive
role.
The effects of each individual miRNA may not apparently be
identical between in-vitro and in-vivo setups. For example, while
miRNAs-34a and -185 exhibited strong anti-proliferative effects
in-vitro (Figure 4B), they affected much more moderately tumor
growth rate in-vivo (Figure 7A). This could be attributed to a major
difference in expression intensity between in-vitro and in-vivo
settings (Figure 4A and 7C). Nevertheless, the in-vivo experiments
suggest that even when the over-expression level is relatively weak
(Figure 7C), an experimental outcome that takes into account
several biological processes, such as tumor growth, can still reflect
the suppressive effect of the over-expressed miRNA (Figure 7).
Moreover, these experiments simplify the possibility of combina-
torial regulatory effects of different miRNAs, which can work
either in concert or interference [44]. Thus, a coordinated
downregulation and upregulation of miRNAs may shape a certain
phenotype even when the alterations in each miRNA expression
level are not extreme. Indeed, we have observed several direct and
inverse statistical correlations between the tested Suppressive
miRNAs in the clinical melanoma specimens, which could suggest
synergistic or antagonistic effects among them (data not shown).
The outcome of the interactions between the different Suppressive
Figure 5. Candidate Suppressive miRNAs inhibit tube formation by melanoma cells. Tube formation ability of transductants was tested in
3D culture, 24 h after seeding. Each experiment was performed in triplicate wells. (A) A representative microphotograph of a 3D culture of Mock-
transduced HAG cells; (B–F) Representative microphotographs of miRNA-transduced HAG cells, as indicated in each picture. All images were captured
under 640 magnification. All pictures (A–F) were derived from the same representative experiment shown, out of three performed. (G) Tube
formation was quantified using the ImageJ analyze skeleton PlugIn. Figure shows the average length calculated for each transductant out of all
microphotographs captured in all three experiments performed. * denotes P,0.05, ** denotes P,0.01 (2-tailed t-test).
doi:10.1371/journal.pone.0018936.g005
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standing of phenotype shaping by combinatorial miRNA patterns,
and since synergistic inhibitory combinations could provide a solid
lead for innovative therapy.
In conclusion, this is the first report that successfully
demonstrated a systematic approach for identification of miRNAs
that directly regulate aggressive cancer features. We described six
miRNAs contributing to the aggressive phenotype of cutaneous
melanoma both in-vitro and in-vivo, and linked these observations to
clinical samples. Identification of miRNAs that shape the
aggressive phenotype of the disease may lead to the development
of innovative future therapy and molecular staging systems.
Recent publications showed the possibility of targeting experi-
mental melanoma metastases using nanoparticles carrying miR-
34a [45] or a synthetic miRNA agonist [46].
Materials and Methods
Ethics Statement
All animal work in mice was performed following approval of an
Institutional Review Board of Sheba Medical Center (562/2010).
All clinical samples derived from patients, from which melanoma
cultures were establish, were obtained following approval of the
ethical committee of the Israel Ministry of Health (IMoH approval
No. 3518/2004). All patients have willingly signed on an informed
consent form.
Cells
The two isogenic human cutaneous melanoma cell lines C8161
cells (Highly aggressive - HAG) and the poorly aggressive C81-61
(Poorly aggressive - PAG) [29] were kindly provided by Dr Mary
Hendrix (Children’s Memorial Research Center, Chicago, USA).
These cell lines were derived of two different metastases from the
same patient. Primary melanoma cultures were developed from
surgically removed metastatic melanoma lesions (IMoH approval
No. 3518/2004) and were grown as previously described [47].
PAG cells were grown in Ham’s F10 medium supplement with
Figure 6. Candidate Oncogenic miRNA enhance proliferation
of melanoma cells. (A) Verification of miR-17-5p over-expression in
PAG transductants, as compared to mock-transduced cells. Y-axis
denotes fold change above Mock-transduced cells. (B) Net proliferation
of the PAG transductants was quantified with standardized XTT test.
The number of cells was determined 48 h after seeding. The number of
Mock-transductants was determined as 100%. Figure shows a
representative experiment out of 3 performed. (C) Invasion activity of
PAG transductants was quantified with 20 h-matrigel invasion assay,
with correction for proliferation. Y-axis denotes the percentage of
invaded cells. Figure shows a representative experiment out of three
performed. ** denotes P,0.01 (2-tailed t-test).
doi:10.1371/journal.pone.0018936.g006
Figure 7. Suppressive miRNAs inhibit tumor growth in-vivo. (A)
Monitoring of tumor growth in SCID-NOD mice. Each group was
comprised of seven mice. A representative experiment out of four
performed is shown. Statistical significance was tested with 2-tailed-
paired t-test; (B) Mean weight of tumors explanted upon termination of
the experiment. Statistical significance was tested with 2-tailed t-test; (C)
Over-expression of transduced miRNAs was confirmed upon termina-
tion of the experiment in all tumors with qPCR. * denotes P,0.05.
doi:10.1371/journal.pone.0018936.g007
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Human Epidermal Melanocytes were maintained in a serum free
unique medium (PromoCell). 293T cells (ATCC) were maintained
in DMEM (Gibco/Invitrogen) containing 10% FBS (DMEM/
FBS).
miRNA expression analysis
Total RNA was isolated using the mirVana miRNA Isolation
Kit (Ambion). High-throughput screening of miRNA was
performed by real time PCR using TLDA format TaqMan
MicroRNA kits (Applied Biosystems). Expression of specific
miRNAs and U6 RNA (as endogenous control) was performed
following reverse transcription from ,200 nt RNA fractions, using
the TaqMan MicroRNA kits (Applied Biosystems). Cutoff levels
for significance were determined as at least 4-fold ratio between
tested samples and cycle 36 as the limit for expression range, based
on our previous evaluation of this technology. Quantification of
miRNAs expression in xenografts was performed following tumor
excision, homogenization (Polytron homogenizer) in Tri reagent
(Sigma) and RNA purification with Trizol.
Cloning of miRNAs into mammalian expression vector
Genomic DNA was extracted from cells with the Wizard
Genomic DNA Purification Kit (Promega). miRNAs were
amplified with PCR from genomic DNA using specific primers
(Supplementary Table S3). Each amplified miRNA included the
flanking genomic sequences of 110 bp from both sides. The
amplicon was cloned into the pQCXIP vector (CloneTech) using
the NotI and EcoRI restriction enzymes (New England BioLabs).
Empty pQCXIP served as negative control. All cloned constructs
were fully sequenced.
Cell transductions
2610
5 293T cells were seeded in a 6-well plate and cultured
overnight in DMEM (Gibco/Invitrogen) containing 10% FBS
(DMEM/FBS). On day 1, cells were transfected with a mixture of
1 mg GAG-POL, 1 mg Envelope, 2 mg of each of the pQCXIP
constructs and 6 ml of Turbofect reagent (Fermentas). After six
hours of incubation at 37uC, the cells were washed and re-cultured
in fresh DMEM/FBS. On day 2, 5610
4 melanoma cells were
placed in each well of 6-well plates and cultured overnight in
DMEM/FBS. On day 3, the melanoma cells were infected with
6 ml of 0.45 mm-filtered virion-containing medium of the 293T
cells. After incubation at 37uC for 6 hours, the infected melanoma
cells were washed and re-cultured with fresh DMEM./FBS. The
aforementioned infection procedure was repeated the next day on
the same melanoma culture. 48 hours after the second infection,
selection was performed by addition of 1.2 mg/ml puromycine into
culture medium.
Net cell proliferation
Melanoma cells (3610
3) were seeded in triplicate wells in 96F-
well microplates. Net proliferation was determined by XTT
colorimetric assay (Biological-Industries), according to manufactur-
er’s instruction. Following background subtraction, the O.D. values
were transformed into viable cells counts according to the specific
regression equation that was determined for each cell line tested.
Invasion assay
Melanoma cells (2610
5) were seeded in the upper wells of
Transwell invasion system on Matrigel (BD) coated ThinCerts
PET 8-mm membranes (Greiner-bio-one) in RPMI 1640 supple-
mented with 0.1% FBS. The lower well contained the same
medium with 10% FBS. After 24 hours of incubation in
humidified 5% CO2 incubator, the upper well content, which
contained non-invading cells, was removed using cotton swabs.
The amount of cells that invaded through the membranes was
measured by standardized XTT staining (as above) and corrected
for proliferation. Percent of invasion was calculated out of the
number of cells seeded.
Tube formation assay and image analysis
Tube formation activity in-vitro on Matrigel (BD) was deter-
mined in 96-well microplates as previously described [48]. Tube
formation was quantified after 24 h by an image analysis process
using whole field image capture (640 microscopic images) to avoid
any bias. In principle, we quantified the distribution of the network
lengths. First, a threshold was manually set to specifically
demonstrate the network structures in the image. The quality
and resolution of the images allowed reliable and exclusive
threshold of the networks without the need of image filtering.
Images were then placed in bins and subjected to the
‘‘Skeletonize’’ function of ImageJ software. The corresponding
lengths was measured using the 2D/3D skeleton PlugIn [49] for
the NIH ImageJ software [50].
Human melanoma xenograft model in SCID-NOD mice
3610
5 miRNA transfected HAG cells were injected subcuta-
neously to the thigh of 8w old SCID-NOD mice to create human
melanoma xenografts. Experimental groups included control cells
and miRNA over-expressing cells. Each group included at least 6
mice. Mice were monitored 3 times per week for tumor volume by
caliper measurement. Tumor volume was calculated as (small
diameter)
26(large diameter)/2. At termination of each experi-
ment, tumor masses were extracted, weighed, photographed and
snap frozen in liquid nitrogen. All animal work was performed
following approval of an Institutional Review Board of Sheba
Medical Center (562/2010).
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